These resources are designed to support clinicians in the management of individuals with opioid use disorder. These clinical guides focus on evidence-based pharmacotherapy and integrated care protocols to improve patient outcomes and system-level safety.
Methadone for Opioid Use Disorder: Indications, Contraindications, and Precautions
This technical resource outlines the clinical parameters for utilizing methadone as a cornerstone of comprehensive opioid use disorder (OUD) treatment. It details specific indications for use, such as transitioning from high-dose buprenorphine, while providing a rigorous screening list of contraindications and cardiac precautions. The guide serves as a vital safety reference for clinicians to manage respiratory risks, pregnancy considerations, and the prevention of precipitated withdrawal during induction or maintenance.
Methadone Induction: Initial Workup and Cardiovascular Safety
Focused on the critical preparation phase, this resource establishes a standardized protocol for the initial medical workup and cardiovascular risk stratification of patients starting methadone. It provides a comprehensive checklist for history-taking, physical examinations, and essential laboratory testing, with a specialized emphasis on monitoring QTc intervals to mitigate cardiac risks. Additionally, the guide includes practical instructions for baseline bowel function assessment and medication review to optimize patient safety before and during induction.
Methadone Dosing, Titration, and Ongoing Monitoring
This clinical resource provides a granular roadmap for the induction and long-term supervision of methadone therapy, categorized by patient tolerance levels. It emphasizes the “start low, go slow” philosophy, offering specific day-by-day dosing schedules for healthy, low-tolerance, and non-tolerant individuals to mitigate the high risk of overdose during the initial accumulation phase. The guide details essential monitoring protocols, including peak/trough serum level analysis, QTc tracking, and managing complex drug-drug interactions involving CYP3A4 inhibitors and inducers, to ensure sustained therapeutic stability and safety.